Replies to post #86 on Abbott Laboratories (ABT)

[DewDiligence]

ABT ‘ReadMeFirst’ updated:

ABT licenses anti-CD4 mAb from Biotest AG;
Bardoxolone advances to phase-3;
ABT submits PMA for Crizotinib diagnostic;
ABT is a beneficiary of The Global Diabetic Tailwind;
NIH terminates AIM-HIGH study;
“Once is happenstance, twice is coincidence, three times…”

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=64633397